Elekta to Launch AI-Enabled Elekta Evo CT-Linac for Adaptive Cancer Therapy

Elekta develops precision-focused radiation therapy solutions and works with partners to advance sustainable, outcome-driven cancer care.

Elekta, a global precision radiation therapy company, is preparing to launch Elekta Evo, an advanced AI-enabled CT-Linac (linear accelerator) developed to deliver Adaptive Radiation Therapy (ART) for cancer care.

India records over 1.4 million cancer cases annually, with a significant number detected at later stages. Elekta Evo aims to support clinicians by enabling real-time precision therapy, which is expected to strengthen treatment outcomes and improve patient quality of life.

ART is a modern radiotherapy approach that adapts each treatment session based on real-time tumour changes, including shape, size, and location. By ensuring radiation is delivered with high accuracy, the technique enhances both the safety and effectiveness of therapy.

Moreover, according to the company, clinicians also gain greater control during treatment, while patients benefit from reduced side effects.

The relevance of ART continues to grow in India, where head and neck cancers represent nearly 30 per cent of all cases. Breast and cervical cancers remain the most prevalent among women, while prostate cancer is the third most common among men.

Elekta develops precision-focused radiation therapy solutions and works with partners to advance sustainable, outcome-driven cancer care. The company is headquartered in Stockholm, Sweden, and operates in more than 40 countries with a global workforce of 4,500 employees. 

Stay tuned for more such updates on Digital Health News